Effectiveness and Safety of Bedaquiline-Containing Modified Shorter Regimens for Multidrug- or Rifampicin-Resistant Tuberculosis: A Single-Arm Meta-Analysis.

Abstract readMeta-AnalysisReview

In one paragraph

Synthesis in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yihui ZhouThe Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.

Hongxia NiuSchool of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID 0000-0001-5367-3813

Funding

National Natural Science Foundation of China Youth Foundation 81701969Natural Science Youth Exploration Program 2022JKZKTS03Open fund for the State Key Laboratory of Pathogenic Biology of Animal Diseases SKLVEB2021KFKT002Zhejiang Provincial Natural Science Foundation of China LY24H290004

6 · The paper itself

Abstract

Tuberculosis (TB) remains a global public health emergency, with multidrug-resistant TB (MDR-TB) and rifampicin-resistant TB (RR-TB) posing critical challenges. Conventional longer regimens are characterized by suboptimal effectiveness, high toxicity, and poor tolerability. Consequently, there is an urgent demand for more effective, safer, shorter regimens with enhanced tolerability to replace traditional treatments. The present study aimed to systematically assess the effectiveness and safety of bedaquiline-containing modified shorter regimens (adaptations of the WHO-recommended 9-12-month bedaquiline-containing shorter regimen, with ethionamide, ethambutol, isoniazid, and pyrazinamide partially or fully substituted by linezolid, cycloserine/terizidone, and/or delamanid) for MDR/RR-TB. Databases (PubMed, Cochrane Library, Embase, and Web of Science) were searched up to 17 December 2025. Data on treatment success, adverse events, and patient characteristics were extracted. Heterogeneity was assessed using Cochrane Q test and I

Indexed as

Antitubercular AgentsDiarylquinolinesRifampinTuberculosis, Multidrug-ResistantDrug Therapy, CombinationHumansMycobacterium tuberculosisTreatment OutcomeAntitubercular AgentsbedaquilineDiarylquinolinesRifampinbedaquilinemeta-analysismultidrug-resistant tuberculosisrifampicin-resistant tuberculosis

Identifiers

PMID41754383

DOI10.3390/pathogens15020130

PMCPMC12943216

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.